Which physical change would the nurse tell the female patient (transitioning from female to male) beginning testosterone therapy to anticipate? Select all that apply.

A. Increased sweating: Dicyclomine is an anticholinergic agent, which typically reduces sweating rather than increases it. In fact, patients may be at risk for heat-related illness due to decreased ability to sweat effectively in hot environments.

B. Frequent urination: Anticholinergic drugs like dicyclomine generally cause urinary retention, not frequency. Clients may actually report difficulty initiating urination or decreased urinary output while on this medication.

C. Weight gain: Weight gain is not a common side effect of dicyclomine. It is not associated with metabolic changes or appetite stimulation significant enough to cause noticeable weight increase in most patients.

D. Dry mouth: Dry mouth is a frequent and expected anticholinergic side effect of dicyclomine. It results from the medication’s inhibition of salivary gland secretion, and patients should be advised to sip water or use sugar-free candy to manage it.

A. Naloxone: Diphenoxylate is an opioid derivative used to treat diarrhea, and naloxone is an opioid antagonist that reverses its central nervous system and respiratory depressant effects in overdose. It is the drug of choice in this situation.

B. Flumazenil: Flumazenil is a benzodiazepine antagonist used to reverse the effects of drugs like diazepam or lorazepam. It has no therapeutic effect on opioid toxicity and would not be useful here.

C. Digibind: Digibind is an antidote used specifically for digoxin toxicity. It binds to circulating digoxin to neutralize its effects, but it has no role in opioid-related overdoses.

D. Glucagon: Glucagon is used in cases of beta-blocker overdose or severe hypoglycemia. It is not effective against diphenoxylate toxicity and would not be administered in this context.